<![CDATA[Novel Agent Validates Hepicidin-Agonist Approach in Polycythemia Vera]]>

Data ReadoutpositiveDISC-3405Positive

AI Analysis

Summary

DISC-3405, a novel hepcidin-agonist agent, demonstrates validation of the hepcidin-agonist approach in polycythemia vera and may function as an adjunctive therapy alongside hydroxyurea or interferon.

Outcome Details

Novel hepcidin-agonist agent DISC-3405 validates approach in polycythemia vera; may serve as adjunctive therapy with hydroxyurea or interferon

Importance:6/10

Sentiment:

0.60

polycythemia verahepcidin-agonistadjunctive therapyclinical data

Related Companies

$VERA

Read the original article

Published by Cancer Network on September 11, 2026 12:00 PM

Read Original